3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
20
atezolizumab
9
Nivolumab
9
Gemcitabine
9
Docetaxel
5
avelumab
4
Mitomycin
4
Carboplatin
4
fludarabine
3
epacadostat
3
enfortumab vedotin
3
Cyclophosphamide
3
vofatamab
2
valrubicin
2
rucaparib
2
pemigatinib
2
durvalumab
2
cabozantinib
2
Standard of Care
2
Sirolimus
2
Radiation
2
Pemetrexed
2
Cisplatin
2
Bevacizumab
2
B701 protein, Human herpesvirus 6
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
trilaciclib
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Transitional Cell
×
trilaciclib
×
Clear all
NCT04887831
2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2
Terminated
92 enrolled
24 charts